%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-01-16T13:17:08+05:30
2017-01-16T13:17:08+05:30
2017-01-16T13:17:08+05:30
Adobe InDesign CS6 (Macintosh)
uuid:aaa249f7-0c21-5b4e-a375-b9cb29f5725f
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.id:AEE5592112206811822ACB128E595E5F
proof:pdf
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2017-01-16T13:17:08+05:30
xmp.iid:40FC28DF10206811822ACB128E595E5F
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.did:01801174072068118DBB881A9EDFAAFA
default
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
28 0 obj
<>stream
q
/GS0 gs
/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
11 0 0 11 36 42.6404 Tm
(70)Tj
ET
q
0 g
/GS0 gs
/Fm1 Do
Q
BT
/TT0 1 Tf
0.071 Tw 11 0 0 11 36 688.9917 Tm
[(blind, such as using a double-dummy placebo )-0.6(when )]TJ
0.015 Tw 0 -1.182 TD
[(pills look dif)18(ferent \(like aspirin vs. )0.7(ibuprofen)]TJ
0 Tw 6.82 0 0 6.82 246.476 680.1717 Tm
(3)Tj
0.015 Tw 11 0 0 11 250.2689 675.9917 Tm
[(\) )0.5(or even )]TJ
0.028 Tw -19.479 -1.182 Td
[(employing some )0.5(simulation)-1( )0.6(to )0.6(mimic the )0.5(appearance )]TJ
0.135 Tw T*
[(of )0.6(the intervention \(e.g. )0.6(acupuncture vs. )0.7(sham acu)]TJ
0 Tw (-)Tj
0 -1.182 TD
(puncture)Tj
6.82 0 0 6.82 78.8076 641.1717 Tm
(4)Tj
0.276 Tw 11 0 0 11 82.6006 636.9917 Tm
[(\). )0.8(Double-blindin)-2.1(g )0.5(is )0.5(the )0.5(best )0.5(practice of )]TJ
0.142 Tw -4.236 -1.182 Td
[(allowing )-1.5(neither the patien)-0.7(t nor )-0.6(the administrator )-1.1(to )]TJ
0.157 Tw 0 -1.182 TD
[(discern the nature of the intervention )-0.6(administered, )]TJ
0 Tw 0 -1.182 TD
[(so every ef)17.9(fort should be taken to achieve this end.)]TJ
/TT1 1 Tf
0.442 Tw 1.636 -1.773 Td
[(Q10: How )0.5(much )0.5(missing )0.7(data or loss to )]TJ
0 Tw 21.818 0 Td
( )Tj
0.05 Tw -23.455 -1.182 Td
[(follow-up )1.5(do )0.8(you )0.6(anticipate )0.5(and )0.6(how )0.9(will )1.1(we )0.5(deal )]TJ
0 Tw 0 -1.182 TD
(with it?)Tj
/TT0 1 Tf
0.226 Tw 1.636 -1.773 Td
[(In )0.7(a )0.7(perfect )0.7(world, we would have data for )0.7(all )]TJ
0.176 Tw -1.636 -1.182 Td
[(study subjects in all measured variables. However)54.3(, )]TJ
0.32 Tw T*
[(instrument malfunctions, misplaced charts, )0.7(patient )]TJ
0.292 Tw T*
(drop-out, and a many other issues may result in )Tj
0.295 Tw T*
[(missing data. )0.9(While other )0.6(articles)]TJ
0 Tw 6.82 0 0 6.82 210.3537 485.1717 Tm
(5)Tj
0.295 Tw 11 0 0 11 214.1466 480.9917 Tm
[( )0.7(better )0.5(address )]TJ
0.008 Tw -16.195 -1.182 Td
[(this subject, one may gene)-0.6(rally avoid replacing )-0.8(miss)]TJ
0 Tw (-)Tj
0.097 Tw T*
[(ing data with values obtained )-0.6(or computed from the )]TJ
0.008 Tw 0 -1.182 TD
[(non-missing )-0.7(data. )55.6(A)55.2( concrete )]TJ
/TT2 1 Tf
0 Tw 13.15 0 Td
(apriori )Tj
/TT0 1 Tf
0.008 Tw 3.064 0 Td
[(plan to )0.5(minimize )]TJ
0.111 Tw -16.214 -1.182 Td
(missing data is much better than an )Tj
/TT2 1 Tf
0 Tw (ad-hoc)Tj
/TT0 1 Tf
0.111 Tw 19.899 0 Td
( statisti)Tj
0 Tw (-)Tj
/C2_0 1 Tf
-19.899 -1.182 Td
[<00460044004F0003>-148.2<00BF005B00110003>-147.6<0029005200550003>-147.9<0048005B004400500053004F0048000F0003>-148.4<0056004800570057004C0051004A0003>-148.1<00440003>-148<00460058005700520049>18.1<00490003>-147.7<0049005200550003>-147.8<00440046004600480053005700440045004F00480003>]TJ
/TT0 1 Tf
0.074 Tw 0 -1.182 TD
[(missing )-0.6(data \(5-10%\) )-0.6(with contingencies )-1.2(for missing )]TJ
0.181 Tw T*
[(those benchmarks )-0.6(like retraining )-0.9(staf)18.3(f, recontacting )]TJ
0.039 Tw T*
[(patients, or instituting a protocol change )-0.7(can prevent )]TJ
0.211 Tw 0 -1.182 TD
[(issues with missingness. )-0.8(Furthermore, designing )-1.3(a )]TJ
0.016 Tw 0 -1.182 TD
[(patient-friendly study at )0.7(the )0.7(onset to )0.6(minimize patient )]TJ
0.067 Tw T*
[(loss-to-follow-up )-0.6(may )0.5(avoid such contingencies alto)]TJ
0 Tw (-)Tj
-0.001 Tw T*
[(gether)54.7(. )55.1(Again)-0.6(, the goal )-0.9(of planning )-1.5(for missing )-0.9(data is )]TJ
0.028 Tw T*
[(to )0.6(maximize the )0.5(chance that )0.6(this study )0.5(contributes to )]TJ
0 Tw 0 -1.182 TD
(the literature.)Tj
ET
q
0 0 612 792 re
W n
BT
/TT3 1 Tf
/Span<>> BDC
14 0 0 14 36 271.4917 Tm
(C)Tj
EMC
9.8 0 0 9.8 46.1104 271.4917 Tm
(ONCLUSIONS)Tj
ET
Q
BT
/TT0 1 Tf
0.226 Tw 11 0 0 11 54 246.4917 Tm
[(The goal of good study design )-0.6(is to maximize )]TJ
0.167 Tw -1.636 -1.182 Td
[(the probabilit)-0.8(y of success while minimizing )-0.8(the risk )]TJ
/C2_0 1 Tf
0 Tw 0 -1.182 TD
[<005700520003>-106.4<0056005700580047005C0003>-106.6<005600580045004D004800460057005600110003>-88.6<0037>111<00520003>-106.6<0057004B004C00560003>-106.6<004800510047000F0003>-106.7<0052005100480003>-106.9<005100480048004700560003>-107.1<00440003>-106.6<0056005300480046004C00BF00460003>]TJ
/TT0 1 Tf
-0.005 Tw 0 -1.182 TD
[(and testable hypothesis with an estimate of the ef)18.1(fect )]TJ
0.062 Tw 0 -1.182 TD
[(size of the intervention )-0.7(in order to adequately )-0.9(power )]TJ
0.345 Tw T*
[(a study)74.2(. Once powered, )-1(randomization )-1.6(with )-0.6(dou)]TJ
0 Tw (-)Tj
0.152 Tw T*
[(ble-blinding )-2(is the best practice )-0.8(to reduce )-0.8(bias, )-0.6(but )]TJ
0.092 Tw T*
[(baseline )-1.1(characteristics )-0.7(should )-0.8(still be collected )-0.8(and )]TJ
0.031 Tw T*
[(compared )-0.7(to exclude )-0.7(the possibility )-0.8(of a confounding )]TJ
-0.07 Tw 0 -1.182 TD
[(variable )-0.9(as the underlying )-1.2(causal )-0.6(factor)55.2(. Having )-0.8(a con)]TJ
0 Tw (-)Tj
0.008 Tw 0 -1.182 TD
[(crete )0.5(plan to )0.7(acquire study )0.5(subjects representative of )]TJ
ET
0 0 0 1 K
q 1 0 0 1 318 489.7417 cm
0 0 m
258 0 l
S
Q
q 1 0 0 1 318 360.7417 cm
0 0 m
258 0 l
S
Q
BT
/TT0 1 Tf
0.095 Tw 11 0 0 11 318 688.9917 Tm
[(the population of )0.5(interest, along with careful consid)]TJ
0 Tw 23.122 0 Td
(-)Tj
0.111 Tw -23.122 -1.182 Td
[(eration )-0.6(of the factors that might result in systematic )]TJ
0.225 Tw T*
[(missing )-0.6(data also require )-0.7(careful planning. )-1(Finally)73.5(, )]TJ
0.055 Tw 0 -1.182 TD
[(building )-1.3(some stopping )-0.8(rules )-0.6(into your study may be )]TJ
0.106 Tw 0 -1.182 TD
[(useful to ensure )-0.6(that missing )-0.6(values )-0.6(and ef)18.1(fect size )]TJ
0.09 Tw T*
(estimates are in line with your expectations. In gen)Tj
0 Tw (-)Tj
-0.031 Tw T*
(eral, one should strive for a study design and write-up )Tj
/C2_0 1 Tf
0 Tw T*
[<0057004B004400570003>-31.1<004C00560003>-31.2<0056005300480046004C00BF00460003>-31<0048005100520058004A004B0003>-32<005700520003>-31.1<004500480003>-31.4<0046005200500053004F004800570048004F005C0003>-31.8<00550048005300550052004700580046004C0045004F00480003>]TJ
/TT0 1 Tf
-0.029 Tw T*
[(by an indepen)-0.8(dent investigator)54.4(. While )-0.8(this exploration )]TJ
0.143 Tw 0 -1.182 TD
[(was intended)-0.9( to demystify the statistical process of )]TJ
0.08 Tw 0 -1.182 TD
[(experimental )-1(study design, )-0.6(it is by no means a sub)]TJ
0 Tw (-)Tj
0.09 Tw T*
[(stitute for a conversation )-1.1(with )-0.6(a statistician. )-0.6(For sta)]TJ
0 Tw (-)Tj
0.148 Tw T*
[(tistical support or help in designing )-0.8(a study)74.1(, )0.6(please )]TJ
0 Tw T*
[(contact the corresponding author)53.6(.)]TJ
/TT1 1 Tf
10.25 0 0 10.25 318 471.2417 Tm
(Article citation:)Tj
/TT0 1 Tf
[( W)37.4(atkins P)128.8(. Potential Pitfalls of )]TJ
0 -1.195 TD
(Experimental Design. Southwest Respiratory and Critical )Tj
T*
(Care Chronicles 2017;5\(17\):68-70.)Tj
/C2_1 1 Tf
0 -1.195 TD
[<002400580057004B005200550003>37.4<0024004900BF004F004C00440057004C00520051001D>]TJ
/TT0 1 Tf
8.461 0 Td
[( Phillip W)36.6(atkins is a statistician who )]TJ
-8.461 -1.195 Td
[(works in the Clinical Research Institute at )16.6(T)111(exas )17.9(T)111(ech )]TJ
0 -1.195 TD
[(University Health Sciences Center in Lubbock, )15.8(TX.)]TJ
/TT1 1 Tf
T*
(Submitted: )Tj
/TT0 1 Tf
5.5 0 Td
[(1)74.1(1/10/2016)]TJ
/TT1 1 Tf
-5.5 -1.195 Td
(Accepted:)Tj
/TT0 1 Tf
( 12/9/2016)Tj
/C2_1 1 Tf
0 -1.195 TD
<00260052005100C0004C0046005700560003005200490003004C0051005700480055004800560057001D>Tj
/TT0 1 Tf
( none)Tj
ET
q
0 0 612 792 re
W n
BT
/T1_1 1 Tf
13 0 0 13 318 323.2417 Tm
(R)Tj
9.1 0 0 9.1 326.6709 323.2417 Tm
(EFE)Tj
/Span<>> BDC
(R)Tj
EMC
(ENCES)Tj
ET
Q
BT
/T1_0 1 Tf
-0.03 Tc 0.03 Tw 10 0 0 10 318 298.2417 Tm
[(1)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.001 Tw 1.2 0 Td
[(Da)39.8(wson )0.6(B)29.7(., )50.3(T)35(rapp )0.5(R.G. )0.5(Basic )0.6(& )0.5(Clinical )0.5(Biostatistics, )0.6(4th ed. )]TJ
0 Tw 24.6 0 Td
( )Tj
0.164 Tw -24.6 -1.2 Td
[(Ne)24.9(w )90.1(Y)160(ork, NY)91.8(: Lange Medical Books/McGra)39.8(w-Hill; 2001:)]TJ
0 Tw ( )Tj
0 -1.2 TD
(332-343.)Tj
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.2 -1.2 Td
[(2)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.113 Tw 1.2 0 Td
[(Kang )0.5(M, Rag)4.9(an )0.5(BG, )0.5(P)14.8(ark )0.5(JH. )0.5(Issues )0.5(in outcomes )0.5(research: )]TJ
0.143 Tw T*
[(an o)44.9(v)14.9(er)-19.7(vie)24.9(w of randomization techniques for clinical trials. )]TJ
0 Tw 24.6 0 Td
( )Tj
-0.055 Tw -24.6 -1.2 Td
[(J Athl )-5.2(T)34.9(rain. )-55(2008;43\(2\):215-21. )]TJ
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.2 -1.2 Td
[(3)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc -0.058 Tw 1.2 0 Td
[(Nebe J)59.8(, Heier M, Diener HC. Lo)39.8(w-dose ib)-4.9(uprofen in self-med)]TJ
0 Tw (-)Tj
-0.01 Tw T*
(ication of mild to moderate headache: a comparison with ace)Tj
0 Tw (-)Tj
T*
[(tylsalic)14.9(ylic acid and placebo. Cephalalgia. 1995;15\(6\):531-5.)]TJ
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.2 -1.2 Td
[(4)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.06 Tw 1.2 0 Td
[(Mof)24.9(fet )0.6(HH. )0.5(Sham )0.5(acupuncture )0.6(ma)34.9(y )0.6(be )0.5(as )0.5(ef\037cacious )0.6(as )0.5(tr)-19.7(ue )]TJ
0.145 Tw T*
[(acupuncture: a systematic re)24.9(vie)24.9(w of clinical trials. J )54.7(Alter)-19.8(n )]TJ
0 Tw T*
(Complement Med. 2009;15\(3\):213-6.)Tj
/T1_0 1 Tf
-0.03 Tc 0.03 Tw -1.2 -1.2 Td
[(5)-30(.)]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tc 0.068 Tw 1.2 0 Td
[(Dziura JD)59.8(, P)39.8(ost LA, Zhao Q, Fu Z, P)39.8(eduzzi P)159.9(. Strate)14.9(gies for )]TJ
0.169 Tw T*
[(dealing )0.5(with missing )0.5(data in clinical )0.5(trials: )0.5(from design )0.5(to )]TJ
0 Tw T*
[(anal)24.9(ysis. )89.9(Y)139.9(ale J Biol Med. 2013;86\(3\):343-58.)]TJ
ET
endstream
endobj
22 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 272.5411 45.1778 Tm
(The Southwest Respiratory and Critical Care Chronicles 2017;5\(17\):68\226\
70)Tj
ET
endstream
endobj
32 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.5 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 36 59.8957 cm
0 0 m
540 0 l
S
Q
10 M
q 1 0 0 1 36 731.2762 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 36 742.5262 Tm
[(W)18.2(atkins)]TJ
/Span<>> BDC
( )Tj
EMC
49.769 0 Td
(Potential Pitfalls of Experimental Design)Tj
ET
endstream
endobj
34 0 obj
<>
endobj
35 0 obj
<>
endobj
36 0 obj
<>stream
H\n0 {PAiVBH+m%Ѻ= ML4B職WH/b&8AYqn^#\YJtz[S%q¾'?ӳ.Pћ7;{꼀|s{P`4
wӼ!$aWTELDThͿ$K&Ul64SqJN%&4lLY32qƖ,;^gW}G}SQE.